These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20388848)

  • 41. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.
    McClanahan F; Hielscher T; Rieger M; Hensel M; Neben K; Hillengass J; Herfarth K; Ho AD; Witzens-Harig M
    Eur J Haematol; 2010 Jul; 85(1):11-9. PubMed ID: 20331739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
    Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R
    Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.
    Taskinen M; Jantunen E; Kosma VM; Bono P; Karjalainen-Lindsberg ML; Leppä S
    Eur J Cancer; 2010 Sep; 46(13):2506-12. PubMed ID: 20630741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
    Dave SS; Wright G; Tan B; Rosenwald A; Gascoyne RD; Chan WC; Fisher RI; Braziel RM; Rimsza LM; Grogan TM; Miller TP; LeBlanc M; Greiner TC; Weisenburger DD; Lynch JC; Vose J; Armitage JO; Smeland EB; Kvaloy S; Holte H; Delabie J; Connors JM; Lansdorp PM; Ouyang Q; Lister TA; Davies AJ; Norton AJ; Muller-Hermelink HK; Ott G; Campo E; Montserrat E; Wilson WH; Jaffe ES; Simon R; Yang L; Powell J; Zhao H; Goldschmidt N; Chiorazzi M; Staudt LM
    N Engl J Med; 2004 Nov; 351(21):2159-69. PubMed ID: 15548776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.
    Taskinen M; Karjalainen-Lindsberg ML; Leppä S
    Blood; 2008 May; 111(9):4664-7. PubMed ID: 18309035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
    Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
    Griffiths R; Gleeson M; Reyes C; Knopf K; Danese M
    Am J Hematol; 2010 Dec; 85(12):963-7. PubMed ID: 20981680
    [No Abstract]   [Full Text] [Related]  

  • 54. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
    van Oers MH; Tönnissen E; Van Glabbeke M; Giurgea L; Jansen JH; Klasa R; Marcus RE; Wolf M; Kimby E; Vranovsky A; Holte H; Hagenbeek A; van der Reijden BA
    J Clin Oncol; 2010 May; 28(13):2246-52. PubMed ID: 20368567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
    Skrabs C; Müller C; Agis H; Mannhalter C; Jäger U
    Leukemia; 2002 Sep; 16(9):1884-6. PubMed ID: 12200717
    [No Abstract]   [Full Text] [Related]  

  • 57. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.
    Peterson BA; Petroni GR; Frizzera G; Barcos M; Bloomfield CD; Nissen NI; Hurd DD; Henderson ES; Sartiano GP; Johnson JL; Holland JF; Gottlieb AJ
    J Clin Oncol; 2003 Jan; 21(1):5-15. PubMed ID: 12506163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics.
    Muneishi M; Nakamura A; Tachibana K; Suemitsu J; Hasebe S; Takeuchi K; Yakushijin Y
    Int J Clin Oncol; 2018 Apr; 23(2):375-381. PubMed ID: 29063983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
    Matsuda I; Hirota S
    Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP.
    Nichols MM; Ondrejka SL; Patil S; Durkin L; Hill BT; Hsi ED
    Leuk Lymphoma; 2023; 64(8):1433-1441. PubMed ID: 37226602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.